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Abstract: Hair loss is a very common complaint. Patients may describe increased shedding and 
diffuse or localized alopecia. The differential diagnosis of hair loss includes a number of disor-
ders causing cicatricial or noncicatricial alopecias. This paper describes the clinical approaches 
and diagnostic tests that are useful in the evaluation of patients presenting with alopecia. It also 
reviews treatments for noncicatricial alopecias, including androgenetic alopecia, alopecia areata, 
and telogen effluvium, as well as cicatricial alopecias, including lichen planopilaris, its clinical 
variant frontal fibrosing alopecia, and discoid lupus erythematosus.
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Background
There are many resources available for the assessment of patients who present with 
hair loss. Evaluations can be categorized as invasive (eg, scalp biopsies), semi-invasive 
(eg, trichogram), or noninvasive (eg, hair counts, microscopic evaluation, trichoscopy). 
Each of the following approaches, when interpreted with the comprehensive clinical 
picture, can provide valuable insights into patient diagnosis, treatment, and monitoring.1 
This paper reviews the clinical approaches and diagnostic tests that are useful in the 
evaluation of patients presenting with alopecia. We reviewed the PubMed literature 
for evaluative methods and therapeutic interventions for noncicatricial alopecias, 
including androgenetic alopecia, alopecia areata, and telogen effluvium, and cicatricial 
alopecias, including lichen planopilaris, its clinical variant of frontal fibrosing alopecia, 
and discoid lupus erythematosus.
A careful clinical history is essential. In patients complaining of increased hair 
shedding, clinicians should investigate for potential triggers from the 3 months before 
the development of hair loss, including drug intake, systemic illness, or weight loss. 
  Gynecologic history is very important in women, and hormonal evaluation is   indicated 
in women with androgenetic alopecia and a history of irregular menses. Further, a family 
history of hair loss is characteristic in androgenetic alopecia and alopecia areata. 
  Laboratory tests should evaluate iron and vitamin D levels and   thyroid function.2
Clinical evaluation should establish if hair density is normal or decreased and if 
the scalp shows diffuse or patchy alopecia. The severity of hair shedding should be 
assessed by a pull test. The pull test begins with gentle traction on a group of hairs 
(approximately 40–60) on three separate areas of the scalp.3 The hairs extracted by 
this gentle traction are examined microscopically and quantified. A normal or   negative 
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from a single area.3 Microscopically, the hair roots should be 
identified as being in the telogen or anagen phase and checked 
for dystrophy. The telogen roots, which have a club-shaped 
bulb and an absence of an inner root sheath, are the most 
commonly seen in a variety of hair disorders.1 Dystrophic, 
broken hairs are seen in diseases that interrupt the mitotic 
activity of anagen follicles, including alopecia areata and 
systemic chemotherapy.4 Anagen roots, which are darkly 
pigmented and triangular or delta-shaped, are typically seen 
in lymphocytic cicatricial alopecia.4
The wash test is a valuable tool in which the patient col-
lects hairs shed during standardized shampooing.5 In one 
study, hair was washed and all shed hairs were counted 
and divided into groups of 5 cm or longer, intermediate 
length (3–5 cm), and 3 cm or shorter (considered telogen 
vellus hairs). Patients who had at least 10% telogen vellus 
hairs were classified as having androgenetic alopecia.6 The 
modified wash test permits evaluation of the whole scalp. 
One recent study found that dystrophic, anagen hairs were 
present among the shed telogen hairs in patients with pre-
sumed telogen effluvium, who may in fact have alopecia 
areata incognita.7
Trichoscopy, or dermoscopy and videodermoscopy of 
the scalp, may reveal features of a specific type of hair loss. 
As an example, in the case of alopecia areata, a character-
istic “  yellow dot” pattern is often seen, as well as micro-
exclamation hairs and black cadaverized hairs or “black dots” 
(Figure 1).8,9 Dermoscopy in androgenetic alopecia reveals 
greater than 20% diversity in the hair diameter (Figure 2).10 
A brown, depressed halo at the follicular opening can be 
observed in early androgenetic alopecia and yellow dots can 
be seen in advanced cases. Further, a honeycomb-pigmented 
appearance can be appreciated in sun-exposed regions of 
the scalp.11 Dermoscopy of active lesions of tinea capitis 
reveals comma hairs, which are slightly curved, fractured 
hair shafts.9
Dermoscopy of primary and secondary cicatricial   alopecia 
reveals decreased hair density and loss of follicular openings 
(Figure 3).11 In the case of lichen planopilaris and its clinical 
variant, frontal fibrosing alopecia, hyperkeratotic, perifolli-
cular white scales with variable perifollicular erythema and 
Figure 1 Alopecia areata: yellow dots and exclamation mark hairs.
Figure 2 Androgenetic alopecia: hair diameter variability.
Figure 3 Lichen planopilaris: loss of follicular openings and perifollicular casts.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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peripilar white dots can be observed,10 along with blue-gray 
dots with a target distribution around the follicle.12 In the 
case of discoid lupus erythematosus of the scalp, mottled 
dyschromia, follicular plugs, telangiectasias, white central 
plaques, and irregularly distributed blue-gray dots in a speck-
led pattern between the hair follicles may be seen.11 Red dots 
can help distinguish discoid lupus erythematosus of the scalp 
from lichen planopilaris. Red dots appear as erythematous, 
polycyclic, concentric   structures, regularly distributed around 
the follicular   opening.13 In folliculitis decalvans tufted hairs 
and perifollicular pustules can be appreciated.11
A scalp biopsy (the gold standard is a 4 mm punch 
biopsy) can be used for a more definitive diagnosis.14 Scalp 
biopsies can be vertically or horizontally oriented. Vertical or 
longitudinal punch biopsy is appropriate for the assessment 
of alopecias associated with interface changes, lichenoid 
infiltrates, and subcutaneous pathology.15 Only portions of 
a small number of follicular units (2–3) are seen in a given 
tissue section due to biopsy tangentially interrupting the 
characteristic angle of hair follicle growth.16 Thus, only 
10% of the follicles present in the specimen will be visu-
alized.17 Horizontal or transverse biopsy is best taken by a 
4 mm punch biopsy 1–1.5 mm below the epidermal–dermal 
junction and yields follicular pathology and a quantitative 
approach to diagnosis.16 Horizontal biopsy also allows 
complete evaluation of the hair follicles throughout their 
entire length.17
Scalp biopsy is a useful tool for the evaluation of most 
cases of cicatricial alopecia and some cases of   noncicatricial 
alopecia. The ideal location for biopsy depends on the 
  presumed diagnosis. For example, in noncicatricial   alopecia, 
a punch in the center of the lesion is appropriate; in cica-
tricial alopecia, the punch should be taken from areas of 
inflammation.1
Androgenetic alopecia
Androgenetic alopecia, or patterned alopecia, is the most 
common form of hair loss in both men and women and is 
characterized by a progressive loss of hair diameter, length, 
and pigmentation. The genetic inheritance of androgenetic 
alopecia is well known, although the causative genes have 
yet to be elucidated. Androgenetic alopecia is often precipi-
tated and exacerbated by conditions that can induce telogen 
effluvium, including drugs, acute stressors, weight loss, and 
partum. For example, drugs with androgenetic effects, includ-
ing contraceptives containing androgenic progestins and 
hormonal treatments for menopause, may induce or worsen 
androgenetic alopecia.18,19 Due to the progressive nature of 
androgenetic alopecia, treatments should be started early and 
extended to maintain efficacy.
Medical treatments approved by the US Food and Drug 
Administration (FDA) for androgenetic alopecia include 
  topical minoxidil 2% for women and topical minoxidil 
5% and the oral type II 5-α-reductase inhibitor finasteride 
(1 mg/day) for men.20 Many authors advocate the use of 
minoxidil 5% for women, but this is not approved by the 
FDA.21 The oral type I and II 5-α-reductase inhibitor, 
 dutasteride, is also effective at the dosage of 0.5 mg/day but 
is not approved for this indication.22 Topical minoxidil should 
be applied twice daily and used for at least 12 months before 
making a decision regarding efficacy.2
Hair transplantation, which is a surgical method of hair 
restoration, is an option for male and female patients over 
the age of 25 years with substantial hair loss. The degree 
and type of hair loss should be considered, because ideal 
candidates for hair transplantation are those with frontal and 
midfrontal hair loss.20 Follicular unit hair transplantation is 
the gold standard, because it preserves the natural architecture 
of the hair units and gives natural results.23
The loss of progenitor cells, but not stem cells, is evident 
in bald vs non-bald scalp areas in patients with androgenetic 
alopecia. These findings reported by Garza et al support the 
hypothesis that a defect in conversion of hair follicle stem 
cells to progenitor cells plays a role in the pathogenesis of 
androgenetic alopecia.24 This breakthrough could implicate 
a novel model for future treatments.
Alopecia areata
Alopecia areata is a noncicatricial loss of hair in any area 
of the body, with a multifactorial autoimmune pathogenesis 
and an unknown etiology.25 This disease affects up to 2% of 
the population and presents with a wide range of clinical 
heterogeneity.26 Patients with alopecia areata may present 
with a very sudden and dramatic loss of hair. Clinically, 
one or more well circumscribed, smooth, scarless, hair-
less patches that enlarge in a centrifugal pattern can be 
observed. Severe forms involve the whole scalp (alopecia 
areata totalis) or all body hair (alopecia areata universalis). 
Alopecia areata can be associated with other autoimmune 
diseases, including thyroid disease, celiac disease, vitiligo, 
and atopy.27
The first episode of alopecia areata can often resolve 
spontaneously without any medical intervention.27,28 The 
severity of the first episode of alopecia areata is an important 
prognostic factor. Further, response to topical   immunotherapy 
may be associated with a better prognosis. In children, the Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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prognosis is worse. Finally, it has been shown that alopecia 
areata worsens over time.29
Most cases of alopecia areata resolve spontaneously 
within 1 year, but up to 25% of patients develop severe forms 
with total loss of scalp hair (alopecia totalis) or of all body 
hair (alopecia universalis) that often persist indefinitely.27,28 
One study showed in adults that the more severe the disease 
at onset, the more severe the prognosis. In children, the evolu-
tion is difficult to predict, because patients with mild alopecia 
areata also tend to progress to severe forms.29
Available treatments may induce hair regrowth but 
have never been proven to change the course of the disease. 
These include pulsed high doses of oral or intravenous 
steroids, topical high potency steroids under occlusion, 
  photochemotherapy, and topical immunotherapy. Efficacy 
of treatments in patients with alopecia totalis and alopecia 
universalis is poor, with long-term complete regrowth in less 
than 20% of patients.29
Intralesional steroids (triamcinolone acetonide 5 mg/mL) 
are probably the most utilized treatments for patchy alopecia 
areata, although there are no controlled studies that confirm 
efficacy.28 Systemic steroids, which have been used in daily, 
weekly, and monthly pulse regimens with variable success, 
are effective in inducing regrowth and arresting hair loss in 
acute disease.28,30–32 However, the use of systemic steroids is 
limited by the frequent occurrence of relapses after treatment 
tapering or interruption.28 High potency topical corticoster-
oids under occlusion are also effective in alopecia areata 
totalis and universalis, with long-term benefit in approxi-
mately 15% of patients.29
Topical immunotherapy with diphenylcyclopropenone or 
squaric acid dibutylester is a good option in severe   alopecia, 
including alopecia totalis and universalis.33 The goal of 
  treatment is to induce a mild contact dermatitis of the scalp. 
The efficacy of diphenylcyclopropenone has been proven 
by studies that demonstrated hair regrowth limited to the 
treated half side of the scalp.28,34–36 Unfortunately, only a 
few therapies for alopecia areata have been comprehensively 
evaluated in randomized controlled trials.37
Telogen effluvium
Telogen effluvium is the loss of telogen hair due to abnormal 
hair cycling.38 Excessive daily shedding of approximately 
100–200 telogen hairs is typically seen. If hair loss is present 
for less than 6 months, it is labeled acute telogen effluvium. 
However, if hair loss is present for more than 6 months, it 
is labeled chronic telogen effluvium.2 Acute telogen efflu-
vium does not usually produce visible alopecia, because 
  approximately 50% of hair is usually lost before there is an 
apparent reduction of hair density. Possible causes of acute 
telogen effluvium include systemic disease, drugs, fever, 
psychoemotional stress, weight loss, delivery, iron and 
Vitamin D deficiency, inflammatory scalp disorders, interrup-
tion of oral contraceptives, and iron deficiency.2 Treatment 
for telogen effluvium should be focused on the cause. For 
example, most dermatologists prescribe iron supplementa-
tion when the ferritin level is below 30 ng/mL. However, a 
recent study showed no statistically significant increase in 
the incidence of iron deficiency in premenopausal or post-
menopausal women with androgenetic alopecia or chronic 
telogen effluvium vs control subjects.39
Cicatricial alopecia
Cicatricial alopecia includes a group of conditions character-
ized by inflammation and subsequent destruction of the hair 
follicle, resulting in irreversible hair loss. Cicatricial alopecia 
can be primary or secondary. Diseases that primarily affect 
the hair follicle cause primary cicatricial alopecia, which is 
classified as lymphocytic or neutrophilic, based on the type 
of inflammatory cell that predominates. Examples of lym-
phocytic cicatricial alopecia include lichen planopilaris, its 
clinical variant frontal fibrosing alopecia, and discoid lupus 
erythematosus.40 Secondary cicatricial alopecia is caused by 
more systemic disorders, including scleroderma, granuloma-
tous inflammation, such as sarcoidosis, or neoplastic disease. 
The diagnosis of cicatricial alopecia requires pathological 
evaluation. Early diagnosis of cicatricial alopecia is essential 
because the goal of treatment is to slow progression of the 
condition.41
First-line treatments for discoid lupus erythematosus 
of the scalp and lichen planopilaris are potent topical 
  corticosteroids, including fluocinonide 0.025%–0.05% and 
  clobetasol lotion or cream,42–45 and intralesional triamci-
nolone acetonide (4–5 mg/mL and 10 mg/mL).46–48 Oral 
  corticosteroids (1 mg/kg/day or 25 or 50 mg/day for 1 month) 
can be   particularly helpful in the case of rapidly progressive 
disease and can be tapered over 2–4 months.48–50
Other useful therapeutic options include topical 
(1.5%) and oral cyclosporine (4 and 5 mg/kg/day for 
3–5 months).41,44 Hydroxychloroquine was proven effec-
tive in arresting progression of lichen planopilaris, frontal 
fibrosing alopecia, and discoid lupus erythematosus of the 
scalp.51–53 Also, mycophenolate mofetil has been shown to 
be efficacious in treating lichen planopilaris.54,55 Finally, 
doxycycline has shown some efficacy in the treatment of 
lichen planopilaris.51Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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A promising new treatment focus for lichen planopilaris 
is the abnormal peroxisome proliferator-activated receptor 
pathways, which leads to aberrant lipid metabolism in the 
sebaceous gland, a toxic buildup of lipids, and an inflamma-
tory response.56 Improvement of lichen planopilaris following 
treatment with the oral peroxisome proliferator-activated 
receptor-γ agonist, pioglitazone hydrochloride at 15 mg/day 
was recently reported.57
Overall, an aggressive multiple modality therapeutic 
approach is often necessary for the treatment of cicatricial 
alopecia. Unfortunately, treatment failure is common and 
none of the available agents clearly halt the progression of 
cicatricial alopecia.58–60
Conclusion
Overall, there are many useful evaluative approaches to 
aid in the diagnosis of both cicatricial and noncicatricial 
  alopecias. These include scalp biopsies, microscopic 
evaluation, trichoscopy, or hair counts, just to name a few. 
Following diagnosis, a variety of treatments are available. 
Further, promising new treatment modalities are being 
  considered, including those that target hair follicle stem cells 
for the treatment of androgenetic alopecia or the peroxisome 
proliferator-activated receptor pathways for the treatment of 
lichen planopilaris. Continued advances will aid the   clinician 
in effectively treating both cicatricial and noncicatricial 
alopecias in the future.
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